Print Page | Sign In | Join
News & Press: Scientific Advancements

Research finds ethnoracial differences in Alzheimer’s disease

Monday, February 18, 2019   (0 Comments)
Share |

Research finds ethnoracial differences in Alzheimer’s disease

Feb. 18, 2019

 

A study led by Mayo researchers finds that Hispanic-American patients with Alzheimer's disease tend to live longer than other ethnoracial groups.


A team of Mayo Clinic researchers found Hispanic-American patients with Alzheimer's tend to survive significantly longer with the disease than other ethnoracial groups, according to a study published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association. Hispanic-Americans were found to live an average of 12 years with the disease from the time of the onset of symptoms.

"This study utilized one of the largest series of donated brain tissue to date, looking at demographic and clinicopathologic features of Alzheimer's disease across an ethnoracially diverse group of cases," says Melissa Murray, Ph.D., a Mayo Clinic translational neuropathologist and principal investigator at Mayo Clinic's Florida campus.

The research team examined 1,625 brain tissue samples and compared the disease progression and duration in individuals who had self-identified as Hispanic, non-Hispanic white, or African-American. Hispanic-American patients had dementia symptoms characteristic of Alzheimer's at an average age of 70, a year or more earlier than the other groups. They were more likely to have family history of dementia. And they had lower cognitive scores at the end of life. However, the average duration of Alzheimer's — how long patients lived once they had symptoms — was 12 years for Hispanic-Americans, compared to nine years for non-Hispanic whites, and eight years for African-Americans.

About the study

The Mayo Clinic study compared the presence, location and composition of Alzheimer's-related protein clumps, known as tangles, in tissue samples from the Florida Autopsied Multi-Ethnic cohort. Researchers found subtle differences among the ethnoracial groups in the severity of the tangles, but no differences in brain weight were found. Hispanic-Americans were slightly less likely to have the genetic variant, known as APOE ε4, which is thought to increase Alzheimer's risk.

The study also found distinctions in the distribution throughout the brain of specific Alzheimer's proteins and the presence of concurrent neurodegenerative processes, which may be relevant to research looking for biomarkers to diagnose the disease.

The study explored demographic details, such as patients' education and employment, which are considered to have protective effects against cognitive decline. Compared to non-Hispanic whites, Hispanic-Americans and African-Americans were found to have fewer years of education, which coincides with other risk factors for Alzheimer's, such as lower socio-economic advantage and increased cardiovascular disease.

"As the field works toward Alzheimer's therapies, ethnoracial differences should be taken into consideration," Dr. Murray says.

Significance for underrepresented groups

Dr. Murray notes that the study is significant in the size of tissue samples from underrepresented groups. Sixty-seven autopsy-confirmed samples of Alzheimer's came from individuals who had self-identified as Hispanic. Most described themselves of Caribbean origin, primarily from Cuba and Puerto Rico, while a few were of Mexican, Central or South American origin. The study also included brain tissue samples from 19 African-Americans.

"Hispanic- and African-American populations tend to be underrepresented in Alzheimer's research, despite having 1 ½ to two times the risk of getting the disease compared to non-Hispanic white Americans," Dr. Murray says. "Our hope is that our findings will help Hispanic- and African-Americans overcome the historical and cultural barriers that contribute to their reluctance to participate in research. Our findings of longevity may have important implications in terms of addressing disparities in caregiver needs, social and family impact, and cost of care."

What's next

The findings also prompt the next stage of investigations, looking at factors that may influence survival in Hispanic-American patients, says Dr. Murray. Her team will explore psycho-social contributors, such as family support and potential neuro-biologic factors that include protective proteins.

The study was funded by the State of Florida Ed and Ethel Moore Alzheimer's Disease Research Program and the National Institute on Aging. Other researchers include Octavio Santos, Ph.D.; Otto Pedraza, Ph.D.; Amanda Liesinger; John  Lucas, Ph.D.; Fadi Hanna Al-Shaikh; Kevin Bieniek, Ph.D.; Kelly Hinkle; Owen Ross, Ph.D.; Nilufer Ertekin-Taner, M.D., Ph.D.; Neil Graff-Radford, M.D.; and Dennis Dickson, M.D. — all of Mayo Clinic — as well as Ranjan Duara, M.D., and Maria Greig-Custo, M.D., of Mount Sinai Medical Center in Florida.


About BioFlorida

BioFlorida represents 6,200 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors that collectively employ 87,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

NEW regional sponsorship opportunities available.

Connect